Natalizumab Completed Phase 1 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01884935PK and PD Study of Natalizumab in Pediatric Subjects With RRMS